Immunohistochemical profiles of claudin-3 in primary and metastatic prostatic adenocarcinoma.
BACKGROUND
Claudins are integral membrane proteins that are involved in forming cellular tight junctions. One member of the claudin family, claudin-3, has been shown to be overexpressed in breast, ovarian, and pancreatic cancer. Here we use immunohistochemistry to evaluate its expression in benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), normal tissue adjacent to prostatic adenocarcinoma (NAC), primary prostatic adenocarcinoma (PCa), and metastatic prostatic adenocarcinoma (Mets).


METHODS
Tissue microarrays were immunohistochemically stained for claudin-3, with the staining intensities subsequently quantified and statistically analyzed using a one-way ANOVA with subsequent Tukey tests for multiple comparisons or a nonparametric equivalent. Fifty-three cases of NAC, 17 cases of BPH, 35 cases of PIN, 107 cases of PCa, and 55 cases of Mets were analyzed in the microarrays.


RESULTS
PCa and Mets had the highest absolute staining for claudin-3. Both had significantly higher staining than BPH (p < 0.05 in both cases) and NAC (p < 0.05 in both cases). PIN had a lower, but non-significant, staining score than PCa and Mets, but a statistically higher score than both BPH and NAC (p < 0.05 for both cases). No significant differences were observed between PCa, Mets, and PIN.


CONCLUSIONS
To our knowledge, this represents one of the first studies comparing the immunohistochemical profiles of claudin-3 in PCa and NAC to specimens of PIN, BPH, and Mets. These findings provide further evidence that claudin-3 may serve as an important biomarker for prostate cancer, both primary and metastatic, but does not provide evidence that claudin-3 can be used to predict risk of metastasis.
University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Tanner L
TL
Bartholow
Uma R
UR
Chandran
Michael J
MJ
Becich
Anil V
AV
Parwani
D000230:Adenocarcinoma / Q000378:metabolism* / Q000473:pathology / Q000556:secondary; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001706:Biopsy; D062465:Claudin-3; D006801:Humans; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism*; D011467:Prostate / Q000378:metabolism / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000378:metabolism / Q000473:pathology; D019048:Prostatic Intraepithelial Neoplasia / Q000378:metabolism / Q000473:pathology; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000556:secondary; D040081:Protein Array Analysis
D014408:Biomarkers, Tumor; C568122:CLDN3 protein, human; D062465:Claudin-3; D008565:Membrane Proteins
Cancer. 2007 Apr 1;109(7):1312-22
17326053
J Biol Chem. 2005 Jul 15;280(28):26233-40
15905176
Cancer Res. 2005 Aug 15;65(16):7378-85
16103090
Int J Cancer. 1982 Jun 15;29(6):611-6
7107064
J Clin Pathol. 2006 Mar;59(3):250-4
16505274
BMC Cancer. 2005 May 13;5:45
15892885
Scand J Urol Nephrol. 1980;14(1):29-35
6154966
Hum Pathol. 2007 Apr;38(4):564-9
17306334
Am J Clin Pathol. 2008 Jul;130(1):43-9
18550469
Ann N Y Acad Sci. 2000;915:129-35
11193568
Am J Physiol Gastrointest Liver Physiol. 2000 Sep;279(3):G477-82
10960345
Annu Rev Physiol. 1998;60:161-77
9558459
Br J Cancer. 2008 Aug 5;99(3):491-501
18648369
Cancer Res. 2005 Nov 1;65(21):9603-6
16266975
Nat Rev Mol Cell Biol. 2001 Apr;2(4):285-93
11283726
J Mol Histol. 2007 May;38(2):113-21
17318343
Diagn Pathol. 2007 Oct 27;2:41
17963516
J Urol. 2005 Nov;174(5):1785-8; discussion 1788
16217287
J Surg Res. 2011 May 15;167(2):e185-91
20462599
Histol Histopathol. 2007 Nov;22(11):1185-95
17647191
Histol Histopathol. 2010 Jan;25(1):83-90
19924644
Mod Pathol. 2008 Nov;21(11):1320-9
18587324
Cancer Res. 2000 Nov 15;60(22):6281-7
11103784
Annu Rev Physiol. 2006;68:403-29
16460278
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
20610543
Cancer Res. 2001 Nov 1;61(21):7878-81
11691807
BMC Cancer. 2006 Jul 12;6:186
16836752
Int J Cancer. 1977 Nov 15;20(5):680-8
924691
Mol Membr Biol. 2002 Apr-Jun;19(2):103-12
12126228
Korean J Urol. 2010 Apr;51(4):239-44
20428425
J Natl Cancer Inst. 2002 Jul 3;94(13):981-90
12096083
Clin Cancer Res. 2003 Jul;9(7):2567-75
12855632